EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
Top Cited Papers
- 30 June 2011
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 59 (6), 997-1008
- https://doi.org/10.1016/j.eururo.2011.03.017
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the BladderEuropean Urology, 2010
- Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic StudyEuropean Urology, 2010
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder CancerEuropean Urology, 2009
- Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancerUrologic Oncology, 2009
- Comparison of Three Schedules of Intravesical Epirubicin in Patients with Non–Muscle-Invasive Bladder CancerEuropean Urology, 2008
- The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical TrialsEuropean Urology, 2008
- Declining mortality from bladder cancer in EuropeBJU International, 2007
- The Effect of Repeat Transurethral Resection on Recurrence and Progression Rates in Patients With T1 Tumors of the Bladder Who Received Intravesical Mitomycin: A Prospective, Randomized Clinical TrialJournal of Urology, 2006
- Effect of Prophylactic Treatment with Intravesical Epirubicin on Recurrence of Superficial Bladder Cancer—The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG):: A Randomized Trial of Intravesical Epirubicin at Dose of 20mg/40ml, 30mg/40ml, 40mg/40mlEuropean Urology, 2004
- A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?European Urology, 2004